The REDEFINE 2 trial examined CagriSema in adults with type 2 diabetes, a population that typically shows less weight loss with GLP-1 therapies
Clinical trial expansion: More rigorous human trials testing peptides for orthopedic applications gradually emerging
Epithalon has been extensively evaluated in aging-prone and cancer-prone rodent models, where it has been shown to reduce spontaneous tumor formation, suppress oncogene expression (notably HER-2/neu), and increase median and maximal lifespan 1,2
Always coordinate with your care team, especially if you use DMTs, steroids, blood thinners, diabetes or thyroid medicines
Still, GLP-1 use may lead to hundreds of thousands of patients experiencing gastrointestinal side effects, according to the researchers